Our licensing partner Verrica Pharmaceuticals today announced that the first patient has been dosed in Part 2 of their Phase II study evaluating our lead compound, LTX-315 - by Verrica designated as VP-315 - for treatment of basal cell carcinoma. 

The progress into Part 2 is based on the positive results from the recently completed Part 1 of the study, where LTX-315 showed clinical evidence of activity in patients who received a higher dose range.   

The CEO of Verrica, Ted White, made this comment: “As a novel oncolytic peptide administered directly at the tumor site, VP-315 has the potential to offer a non-surgical alternative for the approximately 3.6 million cases of basal cell carcinoma diagnosed in the U.S. each year.”

For the entire press release from Verrica, click here.

And for article at MedWatch, click here.